Recommended Vaccinations

Vaccine Brand Names Abbreviation Type Route Indications Booster Recommendations Age Group Adverse Effects Dose & Schedule Contraindications Catch-up Guidelines Storage Conditions Funding/Program Info
HepA - HepB Twinrix Inactivated hepatitis A virus antigen (half the adult dose of Havrix) and recombinant hepatitis B virus surface antigen (the full adult dose of Engerix-B) 1 ml IM Hepatitis A, Hepatitis B 18 years and older 0,2 and 6 months or: Accelerated Schedule: o,1,3 weeks and then 12 months It is not suitable for post-exposure prophylaxis
Cholera, Traveller's Diarrhea Dukoral Inactivated Vibrio cholerae O1 bacteria Recombinant cholera toxin B subunit (rCTB) Oral Cholera, Traveller's Diarrhea 6 years and older: Recommended every 2 years Children aged 2 to 6 years: Recommended every 6 months. > 2 years old Abdominal discomfort Diarrhea Headache 6 years and older: Two oral doses, second dose administered at least one week after the first and at least one week before potential exposure. Children aged 2 to 6 years: Three oral doses, with each dose spaced at least one week apart and completed at least one week before potential exposure Allergy to the vaccine fever or acute gastrointestinal illness Immunocompromised Pregnant or breastfeeding Allergy to formaldehyde
Adenovirus Adenovirus Type 4 & Type 7 Oral Adenovirus 17-50 years 1 dose (2 Tablets)
Anthrax BioThrax AVA Inactivated (cell-free) IM Military, lab workers, at-risk adults Boosters every 12 mo for risk 18-65 years Injection site soreness, fever 3 doses (0, 1, 6 mo) + boosters for risk Severe allergy Complete series Refrigerated (2–8°C) Military, occupational
BCG Generic Live attenuated Intradermal Neonates in high TB-prevalence areas Not recommended Neonates Local ulceration, lymphadenitis Single dose at birth Immunodeficiency, pregnancy Not usually given after infancy Refrigerated (2–8°C) Varies by country
Cholera Vaxchora (oral) Live attenuated Oral Travelers to cholera endemic areas No booster recommended 18-64 years Diarrhea, abdominal pain 1 Dose Severe allergy, immunocompromised Single dose before travel Refrigerated (2–8°C) Travel clinics
COVID-19 Pfizer-BioNTech, Moderna, Novavax mRNA (Pfizer/Moderna), Protein subunit (Novavax) IM All ≥6 months (based on risk & age) Periodic boosters per CDC ≥6 months Fever, fatigue, headache 1–3 doses depending on age & history Anaphylaxis to prior dose Resume based on last dose Ultra-cold or refrigerated Government-funded in many countries
Dengue Dengvaxia Live attenuated SC Prior dengue infection, 9–16 years None 9–16 years Fever, injection site pain 3 doses at 0, 6, 12 months No prior dengue infection, pregnancy Complete 3 doses Refrigerated (2–8°C) Limited regions
DTaP Daptacel, Infanrix Inactivated (toxoid & subunit) IM Children <7 years Not applicable 2 months–6 years Fever, injection site swelling 5 doses: 2, 4, 6, 15–18 mo, 4–6 yrs Encephalopathy, severe allergy Follow CDC catch-up schedule Refrigerated (2–8°C) Covered under VFC
Ebola (rVSV-ZEBOV) Ervebo Live recombinant viral vector IM Outbreak control in endemic areas No booster currently Adults Injection site pain, fever Single dose Severe allergy, pregnancy Complete series Frozen (-70°C) WHO/Emergency use
Hepatitis A Havrix, Vaqta HepA Inactivated IM All children ≥1 year, travelers, high-risk adults None usually Pediatric: 12 months-18 years Adult: ≥19 years Soreness, fatigue 2 doses 6 months apart Severe allergy Complete 2-dose series Refrigerated (2–8°C) VFC, travel programs
Hepatitis B Engerix-B, Recombivax HB HepB Recombinant IM All infants, high-risk adults For immunocompromised or dialysis Pediatric: Birth-19 years Adult: ≥20 years Soreness, fatigue, fever 3 doses (0, 1, 6 mo) Yeast allergy Finish series ASAP Refrigerated (2–8°C) VFC & adult programs
Hepatitis B Heplisav-B HepB Recombinant IM ≥18 years 2 Doses
Hepatitis D No specific vaccine (requires HepB vaccine) N/A N/A Co-infection prevention See HepB All at risk of HepB See HepB Complete HepB series See HepB See HepB See HepB See HepB
Herpes Zoster (Shingles) Shingrix RZV Recombinant subunit IM Adults ≥50 years Not recommended ≥50 years Injection site pain, fatigue 2 doses, 2–6 months apart Severe allergy Complete series Refrigerated (2–8°C) Medicare, adult programs
Haemophilus influenzae type b ActHIB, Hiberix, PedvaxHIB Hib Inactivated (conjugate) IM All children <5 y/o, asplenia Booster at 12–15 months 2 months–5 years Redness, swelling, fever 3 or 4 doses: 2, 4, 6, 12–15 months Severe allergic reaction Based on age and prior doses Refrigerated (2–8°C) Covered under VFC
Human Papillomavirus (HPV) Gardasil® 9 9vHPV Recombinant (virus-like particle) IM Adolescents & young adults (9–26 years); some up to 45 y/o Not required after series 9–45 years Pain, swelling, fainting 2 doses (<15 y/o), 3 doses (≥15 y/o or immunocompromised) Pregnancy, allergy to yeast Complete series if started Refrigerated (2–8°C) VFC, adult programs
Influenza Fluzone®, Fluarix®, Afluria®, Flulaval Inactivated Influenza Vaccine (IIV4) Inactivated (IIV) IM All ≥6 months Annual dose ≥6 months Fever, soreness, nasal symptoms 1 annual dose; 2 if <9 yrs and first time LAIV in immunocompromised Next opportunity Refrigerated (2–8°C) VFC, Medicare, Medicaid
Influenza FluMist® Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) Live attenuated (LAIV) Intranasal 2–49 years (healthy, non-pregnant)
Influenza Fluad® Adjuvanted IIV4 ≥65 years
Influenza Fluzone High-Dose® High-dose IIV4 ≥65 years
IPV (Polio) IPOL Inactivated IM or SC All children, travelers to endemic areas 1 adult booster if at risk 2 months–adult Mild site soreness 4 doses: 2, 4, 6–18 months, 4–6 years Allergy to streptomycin/neomycin Give missed doses Refrigerated (2–8°C) VFC, travel programs
Japanese Encephalitis Ixiaro JE Inactivated IM Travelers to endemic areas, military Booster after 1 year if risk ongoing ≥2 months Injection site pain, fever 2 doses 28 days apart Severe allergy Complete 2-dose series Refrigerated (2–8°C) Travel programs
Lyme Disease None (no licensed vaccine) N/A N/A Prevention in endemic areas N/A N/A N/A N/A N/A N/A N/A N/A
Meningococcal serogroups A, C, W, Y vaccine Menactra® MCV4 MenACWY-D Inactivated (conjugate) IM Adolescents, high-risk groups Booster every 5 years if risk 9 months-55 years Soreness, fever, headache 2 doses: 11–12 years, booster 16 y/o Severe allergy Catch-up doses based on age Refrigerated (2–8°C) VFC, adult programs
Meningococcal serogroups A, C, W, Y vaccine Menveo® MCV4 MenACWY-CRM Inactivated IM 2 months-55 years 2 Doses
Meningococcal serogroups A, C, W, Y vaccine MenQuadfi® IM ≥2 years
Meningococcal B Bexsero (MenB-4C) Recombinant proteins IM High-risk teens, outbreak control No routine booster 10–25 years Injection site pain, fever 2 doses (≥1 month apart) Severe allergy Complete series Refrigerated (2–8°C) Limited programs
Meningococcal B Trumenba (MenB-FHbp) Recombinant proteins IM 10–25 years 2 or 3 doses (0, 1–2, 6 months)
Measles, Mumps, Rubella M-M-R II, Priorix Live attenuated SC Children and adults Not routine booster ≥12 months Fever, rash 2 doses at 12–15 months, 4–6 years Pregnancy, immunosuppression 2 doses ≥4 wks apart Refrigerated (2–8°C) Covered under VFC
Pneumococcal Conjugate (PCV13) Prevnar 13 PCV13 Inactivated (conjugate) IM All children <2 years, adults ≥65 years or risk Additional PPSV23 in adults 2 months–adult Soreness, fever 4 doses: 2, 4, 6, 12–15 mo Severe allergy Catch-up for children Refrigerated (2–8°C) VFC, adult programs
Pneumococcal 23-valent polysaccharide vaccine Pneumovax 23 PPSV23 Inactivated (polysaccharide) IM or SC Adults ≥65, at-risk individuals Revaccination every 5 years if high risk ≥2 years Injection site reactions Single or multiple doses Severe allergy Catch-up per guidelines Refrigerated (2–8°C) Adult programs
Rabies Imovax Rabies, RabAvert Inactivated IM Boosters for ongoing risk All ages Injection site pain, headache 3 (pre-exposure) 5 (post-exposure) Severe allergy Follow exposure guidelines Refrigerated (2–8°C) Travel and occupational
Rotavirus Rotarix RV1 Live attenuated Oral Infants Not recommended 6-32 weeks Mild diarrhea, vomiting 2 doses History of intussusception Complete series before 8 months Refrigerated (2–8°C) VFC
Rotavirus RotaTeq RV5 Live attenuated Oral 6-32 weeks 3 doses (2,4,6 mo)
Smallpox Vaccinia ACAM2000 Live Attenuated vaccinia virus Percutaneous Bioterrorism risk, lab workers Not routine Adults Rash, fever, myocarditis (ACAM2000) Single dose Immunodeficiency, eczema Follow guidelines Refrigerated (2–8°C) Strategic National Stockpile
Smallpox JYNNEOS SC
Tetanus, (reduced) Diphtheria, (reduced) Pertussis Adacel Tdap Inactivated (toxoid & subunit) IM ≥19 y/o once, each pregnancy Td every 10 years 10-64 years Pain, swelling, mild fever 1 dose; Td boosters q10y Severe allergic reaction 1 Tdap followed by Td Refrigerated (2–8°C) VFC, adult programs
Tetanus, (reduced) Diphtheria, (reduced) Pertussis Boostrix Tdap Inactivated IM > 10 years 1 Dose
Diphtheria, Tetanus, Pertussis Daptacel, Infanrix DTaP IM 6 weeks-6 years 5 Doses
Diphtheria, Tetanus, Pertussis Tdap IM Adolescents & adults
Diphtheria, Tetanus Generic DT IM Children < 7 5 Doses
Diphtheria, Tetanus Tenivac, Tdvax Td Booster for adults
Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib), and Hepatitis B Vaxelis 6 weeks through 4 years of age 3-dose series at 2, 4, and 6 months of age 2°C to 8°C (36°F to 46°F)
Tuberculosis (BCG) Generic Live attenuated Intradermal High-risk neonates Not routine booster Neonates Local ulceration Single dose at birth Immunodeficiency Not usually given after infancy Refrigerated (2–8°C) Varies by country
Typhoid Typhim Vi Inactivated IM Travelers to endemic areas Oral: every 5 years; IM: every 2 years ≥2 years GI upset, injection site pain 1 dose every 2 years Severe allergy Catch-up as per travel plans Refrigerated (2–8°C) Travel clinics
Typhoid Vivotif Live attenuated Oral ≥6 years 4 doses over 1 week;
Varicella (Chickenpox) Varivax VAR Live attenuated SC Children and non-immune adults None unless outbreak ≥12 months Rash, fever, injection site pain 2 doses: 12–15 months, 4–6 years Pregnancy, immunocompromised 2 doses ≥4 wks apart if ≥13 y/o Frozen (–15°C or colder) VFC, adult programs
Yellow Fever YF-VAX YF Live attenuated SC Travelers to endemic areas No booster generally needed ≥9 months Fever, headache, injection site pain Single dose; lifelong immunity Severe allergy, immunocompromised, infants <6 mo Vaccination before travel Refrigerated (2–8°C) Travel clinics
Zoster (Shingles) Shingrix Recombinant (subunit) IM Adults ≥50 years, immunocompromised ≥19 y/o Not currently recommended ≥19 years Pain, fatigue, myalgia 2 doses, 2–6 months apart Severe allergic reaction Give missing doses Refrigerated (2–8°C) Medicare, adult programs
WordPress Data Table

Notes

1. Tdap
• Preteens between 11-12 years of age should receive 1 dose of Tdap to help boost their immunity after receiving DTaP during their childhood. If you or someone you know has not received a Tdap vaccine by 11-12 years of age, it is recommended to get one dose at their next visit to the doctor’s office or a pharmacy.
• Tdap is also recommending for woman during every pregnancy, see more information on this below.
• Do NOT get Tdap if you are younger than 7 years of age

2. Td
• 10 years after receiving Tdap, every adult should receive a Td vaccine to keep their immunity strong! In case an adult has not received the Tdap vaccine before, they should get the
• Do NOT get Td if you are younger than 7 years of age.

3. DTaP
• Given 5 times throughout a child’s initial years at 2 months, 4 months, 6 months, 15-18 months, and 4-6 years of age.
• Do NOT get DTaP if you are 7 years of age or older.

4. DT
• Given to children who SHOULD NOT receive the whooping cough (pertussis) part of the vaccine such as an allergic reaction to DTaP.
• Do NOT get DT if you are 7 years of age or older.